117 related articles for article (PubMed ID: 36305687)
1. Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
Hongo F; Ueda T; Takaha N; Tamada S; Nakatani T; Miki T; Ukimura O
Int J Urol; 2023 Feb; 30(2):176-180. PubMed ID: 36305687
[TBL] [Abstract][Full Text] [Related]
2. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Walter S; Weinschenk T; Stenzl A; Zdrojowy R; Pluzanska A; Szczylik C; Staehler M; Brugger W; Dietrich PY; Mendrzyk R; Hilf N; Schoor O; Fritsche J; Mahr A; Maurer D; Vass V; Trautwein C; Lewandrowski P; Flohr C; Pohla H; Stanczak JJ; Bronte V; Mandruzzato S; Biedermann T; Pawelec G; Derhovanessian E; Yamagishi H; Miki T; Hongo F; Takaha N; Hirakawa K; Tanaka H; Stevanovic S; Frisch J; Mayer-Mokler A; Kirner A; Rammensee HG; Reinhardt C; Singh-Jasuja H
Nat Med; 2012 Aug; 18(8):1254-61. PubMed ID: 22842478
[TBL] [Abstract][Full Text] [Related]
3. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
4. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Rini BI; Stenzl A; Zdrojowy R; Kogan M; Shkolnik M; Oudard S; Weikert S; Bracarda S; Crabb SJ; Bedke J; Ludwig J; Maurer D; Mendrzyk R; Wagner C; Mahr A; Fritsche J; Weinschenk T; Walter S; Kirner A; Singh-Jasuja H; Reinhardt C; Eisen T
Lancet Oncol; 2016 Nov; 17(11):1599-1611. PubMed ID: 27720136
[TBL] [Abstract][Full Text] [Related]
5. Editorial Comment to Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
Obara W; Kato R
Int J Urol; 2023 Feb; 30(2):181. PubMed ID: 36345128
[No Abstract] [Full Text] [Related]
6. IMA901: a peptide vaccine in renal cell carcinoma.
Bedke J; Stenzl A
Expert Opin Investig Drugs; 2013 Oct; 22(10):1329-36. PubMed ID: 23899354
[TBL] [Abstract][Full Text] [Related]
7. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
8. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
9. A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
Rampling R; Peoples S; Mulholland PJ; James A; Al-Salihi O; Twelves CJ; McBain C; Jefferies S; Jackson A; Stewart W; Lindner J; Kutscher S; Hilf N; McGuigan L; Peters J; Hill K; Schoor O; Singh-Jasuja H; Halford SE; Ritchie JW
Clin Cancer Res; 2016 Oct; 22(19):4776-4785. PubMed ID: 27225692
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.
Tani K; Azuma M; Nakazaki Y; Oyaizu N; Hase H; Ohata J; Takahashi K; OiwaMonna M; Hanazawa K; Wakumoto Y; Kawai K; Noguchi M; Soda Y; Kunisaki R; Watari K; Takahashi S; Machida U; Satoh N; Tojo A; Maekawa T; Eriguchi M; Tomikawa S; Tahara H; Inoue Y; Yoshikawa H; Yamada Y; Iwamoto A; Hamada H; Yamashita N; Okumura K; Kakizoe T; Akaza H; Fujime M; Clift S; Ando D; Mulligan R; Asano S
Mol Ther; 2004 Oct; 10(4):799-816. PubMed ID: 15451464
[TBL] [Abstract][Full Text] [Related]
12. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.
Obara W; Karashima T; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Inoue K; Katagiri T; Shuin T; Nakamura Y; Fujioka T
Cancer Immunol Immunother; 2017 Jan; 66(1):17-24. PubMed ID: 27757561
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
14. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.
Greten TF; Forner A; Korangy F; N'Kontchou G; Barget N; Ayuso C; Ormandy LA; Manns MP; Beaugrand M; Bruix J
BMC Cancer; 2010 May; 10():209. PubMed ID: 20478057
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.
Flörcken A; Kopp J; van Lessen A; Movassaghi K; Takvorian A; Jöhrens K; Möbs M; Schönemann C; Sawitzki B; Egerer K; Dörken B; Pezzutto A; Westermann J
Hum Vaccin Immunother; 2013 Jun; 9(6):1217-27. PubMed ID: 23458999
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW; Gori S; Izzo F; Mayer-Mokler A; Ascierto PA; Königsrainer A; Ma YT; Sangro B; Francque S; Vonghia L; Inno A; Avallone A; Ludwig J; Alcoba DD; Flohr C; Aslan K; Mendrzyk R; Schuster H; Borrelli M; Valmori D; Chaumette T; Heidenreich R; Gouttefangeas C; Forlani G; Tagliamonte M; Fusco C; Penta R; Iñarrairaegui M; Gnad-Vogt U; Reinhardt C; Weinschenk T; Accolla RS; Singh-Jasuja H; Rammensee HG; Buonaguro L
Clin Cancer Res; 2022 Jun; 28(12):2555-2566. PubMed ID: 35421231
[TBL] [Abstract][Full Text] [Related]
17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.
Westermann J; Flörcken A; Willimsky G; van Lessen A; Kopp J; Takvorian A; Jöhrens K; Lukowsky A; Schönemann C; Sawitzki B; Pohla H; Frank R; Dörken B; Schendel DJ; Blankenstein T; Pezzutto A
Gene Ther; 2011 Apr; 18(4):354-63. PubMed ID: 21068778
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
